Ocata Therapeutics (OCAT) Misses Q2 EPS by 1c

Ocata Therapeutics (NASDAQ: OCAT) reported Q2 EPS of ($0.20), $0.01 worse than the analyst estimate of ($0.19).

As of June 30, 2015, the company had approximately $31.9 million in cash and cash equivalents

“During the quarter, we made significant progress across multiple aspects of our business, most notably towards the initiation of a Phase 2 study in dry AMD and a pivotal study in SMD,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “In addition, the completion of our financing has provided us with resources necessary to fund development of our RPE program, including our dry AMD Phase 2 safety trial with intermediate top line data expected from the first cohort in the second quarter of 2016, a significant potential inflection point for the company. We have also made progress in our preclinical pipeline, most notably with our photoreceptor progenitor program and data from this will be reported later this year.”

For earnings history and earnings-related data on Ocata Therapeutics (OCAT) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Walmart shares fall despite earnings beat
• Holcim to acquire Fermacell from James Hardie for EUR 840M